1Pediatric Critical Care Medicine, Department of Pediatrics, New York Presbyterian Hospital - Weill Cornell Medicine, New York, NY.
2Samuel J. Wood Library - Weill Cornell Medicine, New York, NY.
3Section of Pediatric Critical Care Medicine, Department of Pediatrics, Yale School of Medicine, New Haven, CT.
4Division of Transfusion Medicine, Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN.
5Division of Pediatric Hematology/Oncology, Department of Pediatrics, New York Presbyterian Hospital - Weill Cornell Medicine, New York, NY.
6Division of Pediatric Critical Care Medicine, Department of Pediatrics, Children’s Hospital of Richmond at Virginia Commonwealth University, Richmond, VA.
*See also p. 674.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website (http://journals.lww.com/pccmjournal).
Dr. Zantek received research funding from Octapharma, Bayer HealthCare, Terumo BCT, and she disclosed that she is an executive board member of North American Specialized Coagulation Laboratory, and her husband is an employee of Boston Scientific and has a financial interest in ENDO International PLC. Dr. Sheth received funding from Celgene (related to Luspatercept), Novartis (related to deferasirox), Apopharma (related to deferiprone), and Bluebird Bio (related to lentiglobin therapies). The remaining authors have disclosed that they do not have any potential conflicts of interest.
For information regarding this article, E-mail: [email protected]